Pamrevlumab Trials

Pamrevlumab Trials

Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the treatment of idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, and locally advanced pancreatic cancer.

Pancreatic Cancer

lapis logo

LAPIS Study – FG-3019-087, Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination with Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

For more information on the study, please contact 

Pancreatic CANCER Logo

Precision PromiseSM Platform Study, Phase 2/3, Randomized, Open-label, A Multi-Center Trial Evaluating Multiple Regimens in Patients with Stage IV Metastatic Pancreatic Cancer

For more information on this study, please visit 

Duchenne Muscular Dystrophy

lelantos logo

LELANTOS Study – FG-3019-093 A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Learn more about pamrevlumab, DMD and the purpose of the LELANTOS study here, and download a printable version of this resource 

LELANTOS_two logo

LELANTOS TWO Study – FG-3019-094 A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Ambulatory Duchenne Muscular Dystrophy (DMD)

Learn more about pamrevlumab, DMD and the purpose of the LELANTOS TWO study here, and download a printable version of this resource 

For more information on these studies, please contact

Idiopathic Pulmonary Fibrosis

zephyrus logo

ZEPHYRUS Study – FG-3019-091 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

zephyrus 2 logo

ZEPHYRUS II Study – FG-3019-095 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

For more information on these studies, please contact

Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.